LUMETTI, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.906
AS - Asia 5.144
EU - Europa 3.992
SA - Sud America 749
Continente sconosciuto - Info sul continente non disponibili 201
AF - Africa 138
OC - Oceania 16
Totale 20.146
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.497
SG - Singapore 1.489
IT - Italia 1.343
CN - Cina 1.279
GB - Regno Unito 808
BR - Brasile 570
HK - Hong Kong 528
VN - Vietnam 505
BD - Bangladesh 380
SE - Svezia 363
DE - Germania 287
FI - Finlandia 229
RU - Federazione Russa 213
FR - Francia 202
CA - Canada 201
KR - Corea 182
IN - India 173
ID - Indonesia 121
TR - Turchia 121
UA - Ucraina 99
MX - Messico 70
NL - Olanda 70
JP - Giappone 65
AR - Argentina 61
ES - Italia 58
BG - Bulgaria 55
PL - Polonia 48
IQ - Iraq 38
ZA - Sudafrica 37
IE - Irlanda 34
AT - Austria 33
PK - Pakistan 32
CR - Costa Rica 30
IL - Israele 30
MY - Malesia 26
CO - Colombia 22
PE - Perù 22
BE - Belgio 21
MA - Marocco 21
IR - Iran 20
LT - Lituania 19
CL - Cile 18
EC - Ecuador 18
GT - Guatemala 18
CW - ???statistics.table.value.countryCode.CW??? 17
CZ - Repubblica Ceca 17
NO - Norvegia 17
RO - Romania 17
AE - Emirati Arabi Uniti 16
SC - Seychelles 16
SA - Arabia Saudita 15
VE - Venezuela 15
AU - Australia 14
TT - Trinidad e Tobago 14
TN - Tunisia 13
TW - Taiwan 13
EG - Egitto 12
PY - Paraguay 12
HN - Honduras 11
UZ - Uzbekistan 11
NP - Nepal 10
PH - Filippine 10
CH - Svizzera 9
KE - Kenya 9
NI - Nicaragua 9
PR - Porto Rico 9
TH - Thailandia 9
AZ - Azerbaigian 8
GP - Guadalupe 8
JO - Giordania 8
SV - El Salvador 8
GR - Grecia 7
AL - Albania 6
BH - Bahrain 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
HU - Ungheria 6
JM - Giamaica 6
KZ - Kazakistan 6
BB - Barbados 5
BZ - Belize 5
DZ - Algeria 5
PT - Portogallo 5
SY - Repubblica araba siriana 5
AM - Armenia 4
AO - Angola 4
BO - Bolivia 4
BY - Bielorussia 4
CY - Cipro 4
DK - Danimarca 4
EU - Europa 4
GE - Georgia 4
KG - Kirghizistan 4
KH - Cambogia 4
LB - Libano 4
RS - Serbia 4
UY - Uruguay 4
NG - Nigeria 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
Totale 19.918
Salva come PNG Salva come JPEG
Città #
Ashburn 1.193
Santa Clara 1.018
Singapore 940
San Jose 816
Council Bluffs 540
Hong Kong 521
Fairfield 446
Southend 415
Chandler 414
Hefei 407
Woodbridge 253
London 202
Houston 198
Beijing 192
Nyköping 190
New York 189
Ann Arbor 180
Los Angeles 179
Seattle 174
Seoul 170
Helsinki 166
Wilmington 154
Jacksonville 152
Hanoi 147
Ho Chi Minh City 143
Cambridge 135
The Dalles 129
Modena 122
Milan 121
Chicago 110
Dearborn 109
San Diego 92
Jakarta 89
Bologna 86
Buffalo 73
Lauterbourg 73
Rome 66
São Paulo 63
Princeton 61
Shanghai 58
Atlanta 56
Izmir 55
Sofia 54
Dallas 53
Parma 49
Moscow 48
Frankfurt am Main 45
Munich 45
Orem 44
Toronto 43
Columbus 42
Tokyo 42
Montreal 41
Bremen 39
Naples 39
Boardman 37
Warsaw 37
Florence 36
Salt Lake City 35
Denver 32
Lappeenranta 28
Phoenix 28
Turin 28
Delhi 27
Brooklyn 26
Eugene 25
Paris 25
North Bergen 24
Reggio Emilia 24
Stockholm 24
Guangzhou 23
Kent 23
San José 23
Da Nang 22
Haiphong 22
New Delhi 22
Valencia 22
Amsterdam 21
Johannesburg 21
Mexico City 21
Charlotte 20
Chennai 20
Dublin 20
Mumbai 20
Redondo Beach 20
Redwood City 19
Vancouver 19
Ottawa 18
San Francisco 18
Willemstad 17
Lima 16
Rio de Janeiro 16
Turku 16
Brussels 15
Elk Grove Village 15
Manchester 15
Hillsboro 14
Baghdad 13
Boston 13
Catania 13
Totale 12.474
Salva come PNG Salva come JPEG
Nome #
Systemic sclerosis progression INvestiGation (SPRING) Italian registry: Demographic and clinico-serological features of the scleroderma spectrum 462
Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature 392
Established coronary artery disease in systemic sclerosis compared to type 2 diabetic female patients: a cross-sectional study 364
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 362
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 359
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 342
Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 326
Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature 322
APPLICATION OF CRITERIA FOR THE DIAGNOSIS OF “CLINICAL OSTEOPOROSIS ” IN A POPULATION OF POSTMENOPAUSAL WOMEN FROM EMILIA-ROMAGNA REGION 321
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 320
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 304
Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study 300
COMPLEMENT DEPLETION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB: A MARKER OF CLINICAL EFFICACY? 296
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis 292
Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 290
Beyond cat scratch disease: a case report of bartonella infection mimicking vasculitic disorder 288
Scleroderma Digital Ulcers Complicated by Infection with Fecal Pathogens. 285
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers 284
Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study 282
Assessing hand grasp in patients with systemic sclerosis using the 16-grasp test: Preliminary results from a multidisciplinary study group 281
DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT 278
RETENTION RATE OF ADALIMUMAB AND ABP 501 IN THE TREATMENT OF A LARGE COHORT OF PATIENTS WITH INFLAMMATORY ARTHRITIS: A REAL LIFE RETROSPECTIVE ANALYSIS 277
A SELF-ADMINISTERED QUESTIONNAIRE MAY ALLOW GENERAL PRACTITIONERS TO PERFORM A RAPID SCREENING TO IDENTIFY PATIENTS AT RISK FOR FRAGILITY FRACTURES AND TO ADDRESS THEM TO BONE METABOLISM SPECIALIZED CLINICAL CENTERS 271
Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature 271
Osteomyelitis complicating scleroderma digital ulcers. 270
Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis 269
SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS 268
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 264
Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature 261
AB0611 STRAIN ANALYSIS OF THE RIGHT VENTRICLE USING 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS 252
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study (2023-02-07) 244
Thu0349 autologous fat grafting in the treatment of patients with systemic sclerosis: current experience and future prospects 241
Invited Response on: Comments on "Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study" 238
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 236
Baseline Ultrasound Assessment Improves the Response to Apremilast in Patients with Psoriatic Arthritis: Results from a Multicentre Study 235
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 234
Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients 234
AB0645 CANNABINOIDS IN THE TREATMENT OF PAIN RELATED TO SYSTEMIC SCLEROSIS SKIN ULCERS: OUR EXPERIENCE 233
Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis 230
AB0724 Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 230
The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension 229
Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis 221
One-year clinical experience on the use of Nintedanib in Systemic Sclerosis 220
AB0760 Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 217
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 216
Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study 214
Treatment with Rituximab in Systemic Sclerosis Patients: Our Experience in a Pilot Clinical Trial 213
Predictive Value of DLCO Reduction in Scleroderma Patients Without Cardio-Pulmonary Involvement at Baseline 213
KIENBOCK DISEASE IN A PATIENT WITH SSc: A CASE REPORT 213
EFFICACY OF CERTOLIZUMAB PEGOL FOR DISEASE CONTROL OF PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLARTHRITIS FOLLOWED BY THE JOINT GASTRO-RHEUMATOLOGICAL CLINIC 204
A CALL FOR A COMPREHENSIVE ROLE DEFINITION OF THE STUDY COORDINATOR IN RHEUMATOLOGICAL CLINICAL STUDIES 202
AB0212 LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING 202
A New Promising Role for Selexipag in the Treatment of Scleroderma Vasculopathy: Preliminary Results From a Third Level Italian Scleroderma Center 199
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution 198
THU0600 a case of systemic sclerosis complicated by renal crisis: potential etiopathogenetic role of cytomegalovirus and treatment 192
ACCERTAMENTO DELLA DISABILITÀ NELLE MALATTIE REUMATOLOGICHE (EX L.R. N.4 DEL 19 FEBBRAIO 2008) PROPOSTA DI PROTOCOLLO ORGANIZZATIVO 187
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 186
Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study 185
PROBABILITÀ DI SIEROCONVERSIONE DEL TEST QUANTIFERON DURANTE LA TERAPIA BIOTECNOLOGICA: DATI PRELIMINARI DI UNO STUDIO RETROSPETTIVO CONDOTTO PRESSO L’ARTHRITIS CLINIC DELL’AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA 183
CYCLING VS SWAP TNFi AND IL17i IN PSORIATIC ARTHRITIS: RESULTS FROM THE BIRRA RETROSPECTIVE OBSERVATIONAL STUDY 178
PSYCHIATRIC DISORDERS IN RHEUMATOLOGY: EVALUATION OF A SCREENING PROTOCOL IN 100 HOSPITALIZED PATIENTS 177
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 173
CONFRONTO TRA STRATEGIE DI TERAPIA AVANZATA DI 2° E 3° LINEA NELLA ARTRITE PSORIASICA: RISULTATI PRELIMINARI DALLO STUDIO OSSERVAZIONE RETROSPETTIVO BIRRA 171
Cycling versus swapping strategieswith TNF-α inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice 171
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature 166
POS0604 JAKi’S SURVIVAL RATE AND PREDICTORS OF DISCONTINUATION IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS 162
FRI0442 Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 158
DIFFERENCES BETWEEN SELECTIVE AND UNSELECTIVE JAKi: RESULTS FROM A MULTICENTRIC, REAL LIFE STUDY CARRIED OUT ON PATIENTS WITH RA 157
MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY 156
Erratum: From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution (Dermatology Research and Practice (2018) 2018 (1284687) DOI: 10.1155/2018/1284687) 152
L’IPERTENSIONE POLMONARE: DALLE NUOVE LINEE GUIDA ALLA PRATICA CLINICA 149
OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSI 138
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup— AMulticenter Study 137
Infections of scleroderma digital ulcers: A single center cohort retrospective study 137
Influence of safety warnings on the prescribing attitude of JAK 2inhibitors for rheumatoid arthritis in Italy 136
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis 135
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. 131
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study 129
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology 126
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study 125
First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry 123
Elderly-onset systemic sclerosis defines a distinct clinical subset: analysis from the SPRING registry of the Italian Society for Rheumatology 115
Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study 112
FRI0651 Quantitative chest ct predicts 8-years-mortality and comorbidity in systemic sclerosis 109
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 109
Comparative effectiveness of cycling versus swapping to UL-17 inhibitors after first TNF inhibitor failure in Psoriatic Arthritis: A real- world multicenter study 104
Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al 98
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort 95
The clinical profile of systemic sclerosis without a ‘scleroderma pattern’ at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology 94
Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry 91
Guselkumab effectiveness in real-world settings: Observations from an Italian multicentre study 77
Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry. 76
Menopause in systemic sclerosis: the impact on clinical presentation in a multicenter cross-sectional analysis from the National Registry of the Italian Society for Rheumatology (SPRING-SIR) 71
Age and onset timing of Raynaud’s phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR) 61
Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis 57
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study 50
Exploring Disease-Specific Risk Factors for Vertebral Fractures in Systemic Sclerosis: Insights from the ScleroRER Study Group 44
Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World Study 43
Clinical and serological features of triple autoantibody-­ negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology 39
Impact of Severe COVID‐19 on Interstitial Lung Disease in Autoimmune Systemic Diseases 12
Totale 20.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.166
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.166
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022898 0 0 0 0 47 88 42 91 150 95 243 142
2022/20231.261 157 147 89 114 127 160 51 119 177 19 51 50
2023/2024970 27 61 47 143 196 55 84 98 23 33 74 129
2024/20253.728 121 52 64 233 740 599 313 198 428 145 343 492
2025/20267.573 482 272 520 909 947 500 898 386 701 762 709 487
2026/20272.815 321 627 536 1.067 264 0 0 0 0 0 0 0
Totale 20.146